GU Cancers 2020 | Daniel Petrylak: GU 2020 prostate picks

VJOncology is committed to improving our service to you

Daniel Petrylak

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses his research highlights from the 2020 ASCO GU meeting. Specifically mentioned was the combination of olaparib and cediranib for castrate-resistant prostate cancer and the COSMIC study, which investigated the combination of atezolizumab and cabozantinib for prostate cancer. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter